Drugs used to treat HIV could potentially be used to treat multiple sclerosis in the future, experts have said, after new research showed that people with the virus have a lower risk of MS.
Researchers found that people with a HIV infection have a significantly lower risk of developing the debilitating condition.
They said that chronic dampening down of the immune system as a result of HIV or the antiretroviral drugs used to treat it could be the reason behind the lowered risk.
The MS Society said that while much more research is needed into the subject, the study shows that that antiretrovirals could be a potential future option for treatment for MS.
Researchers from Queen Mary University of London, the University of Oxford and the Prince of Wales Hospital in Sydney examined more than 21,000 HIV-positive patients and compared them to more than five million control subjects.
The HIV patients were treated in hospitals in England between 1999 and 2011.
The study, published in the Journal Of Neurology Neurosurgery And Psychiatry, found that those with HIV were 62% less likely to develop MS than the controls.
“This study provides some encouragement that antiretrovirals could be a potential future option”
The authors wrote: “HIV infection is associated with a significantly decreased risk of developing MS.
“Mechanisms of this observed possibly protective association may include immunosuppression induced by chronic HIV infection and antiretroviral medications,” they added.
Dr Emma Gray, research communications manager at the MS Society, said: “This is a valuable and intriguing new study, and the first to show a significant link between HIV and a reduced risk of MS.
“Much more research is needed to definitively prove whether having HIV or being treated for HIV with antiretrovirals, or even a combination of the two, reduces the risk of someone developing MS,” she said.
“We know that people with MS want new, effective treatments and this study provides some encouragement that antiretrovirals could be a potential future option,” she added.
“Clinical trials are the only way to determine this and the good news is there is a London-based trial ongoing which is aimed at testing one such drug,” said Dr Gray.
- Read the full study paper in the Journal Of Neurology Neurosurgery And Psychiatry